



For New Zealand Healthcare Professionals



**REGISTER  
NOW!**

This presentation to be given by Associate Professor Rob Young is intended for New Zealand primary care and covers topics including diagnosis and management of COPD with relevant 2020 updates.

The objective is to present the latest clinical data and guidance on the appropriate use of inhalers to treat COPD patients and provide practical advice to primary care from both a pharmacological and non-pharmacological perspective.

## **COPD for Primary Care: What now and what's ahead?**

**Wednesday 27th May at 7:00pm**

Presented by:  
**Associate Professor Rob Young**

Stay up to date on future respiratory events by registering at [stayinformed.gskpro.co.nz](http://stayinformed.gskpro.co.nz)

**REGISTER NOW** 

To submit questions, or for any other queries, please email:  
[laura.j.bryant@gsk.com](mailto:laura.j.bryant@gsk.com)

For the best experience, we recommend logging in to access the webinar by 6:45pm.



**Associate Professor Rob Young**

Associate Professor Young is a Consultant Physician in the Department of Medicine, Auckland City Hospital and was promoted to Associate Professor, jointly appointed in the Faculties of Health and Medical Sciences and the School of Biological Sciences at the University of Auckland. Currently he lectures to medical students and post-graduate science students. His research and clinical interests focus on the primary prevention and early diagnosis of the smoking related respiratory diseases COPD and lung cancer. He has been the first to show that COPD and lung cancer are linked at a molecular genetic level through overlapping pathogenetic pathways which are activated by smoking in susceptible smokers.

---

**For additional information regarding GSK products or to report an adverse event, please call Medical Information on 0800 808 500.**

This email is intended for New Zealand healthcare professionals only.

About this email: GSK New Zealand has selected this email to be of interest to you in line with your email preferences, which you can edit or unsubscribe from at any time. You may also visit the website and update your preferences by logging into the [website](#). Please do not reply to this message as this is an inactive mailbox and your message will be automatically deleted. If you have any questions or comments please [contact us](#).

About your privacy: GSK may monitor our technology tools and services (including email, phone, and other communications sent to and from GSK) in order to maintain the security of systems, and to protect our staff, customers and business partners from cyber threats and loss of information. Examples of these monitoring activities include checks for offensive materials, viruses and other malignant code, and unauthorised or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance

with local laws. You can learn about the information that we may process about you, and how we use your information, [here](#).

You can also view our [terms of use](#).

Copyright© 2020 GlaxoSmithKline group of companies or its licensor. All rights reserved.

GlaxoSmithKline NZ Limited  
Registered office, Level 11, 21 Queen Street, Auckland, 1010, New Zealand.

TAPS DA2028AM-PM-NZ-CPU-EML-20May0001